Epidemiology of hematologic malignancies in real-world settings: Findings from the hemato-oncology Latin america observational registry study

Vania Tietsche De Moraes Hungria, Carlos Chiattone, Miguel Pavlovsky, Lina M. Abenoza, Gladys P. Agreda, Jorge Armenta, Celso Arrais, Oscar Avendaño Flores, Fernando Barroso, Ana L. Basquiera, Carmen Cao, Maria S. Cugliari, Alicia Enrico, Laura M. Foggliatto, Kenny M. Galvez, David Gomez, Alvaro Gomez, Daniel De Iracema, Danielle Farias, Lineth LopezWilliam Armando Mantilla, Deborah Martínez, Maria Jose Mela, Carlos E. Miguel, Roberto Ovilla, Luis Palmer, Carolina Pavlovsky, Christian Ramos, Guillermina Remaggi, Rodrigo Santucci, Sergio Schusterschitz, Claudia Lucia Sossa, Elena Tuna-Aguilar, Jorge Vela, Telma Santos, Odin De La Mora, Gerardo MacHnicki, Mariana Fernandez, Paula Barreyro

Producción científica: Artículos / NotasArtículo Científicorevisión exhaustiva

41 Citas (Scopus)


PURPOSE Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL. METHODS This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4). RESULTS Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median followup was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. CONCLUSION The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.

Idioma originalInglés
Páginas (desde-hasta)1-19
Número de páginas19
PublicaciónJournal of Global Oncology
EstadoPublicada - 2019
Publicado de forma externa


Profundice en los temas de investigación de 'Epidemiology of hematologic malignancies in real-world settings: Findings from the hemato-oncology Latin america observational registry study'. En conjunto forman una huella única.

Citar esto